Sofinnova Partners SAS - 31 Mar 2025 SCHEDULE 13G/A Report for Quince Therapeutics, Inc. Common Stock, par value $0.001 per share (QNCX)

Filing Manager
Sofinnova Partners SAS
Reporting Manager
Sofinnova Capital VIII
Security
Quince Therapeutics, Inc. Common Stock, par value $0.001 per share
Symbol
QNCX
Shares outstanding
44,359,667 shares
Disclosed Ownership
1,197,711 shares
Ownership
2.7%
Form type
SCHEDULE 13G/A
Filing time
30 Apr 2025, 16:06:36 UTC
Date of event
31 Mar 2025
Previous filing
14 Feb 2025
SEC
View on sec.gov

Reporting Managers (8)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Sofinnova Capital VIII 2.7% 1,197,711 1,197,711 0 /s/ Antoine Papiernik Antoine Papiernik / Managing Partner
Sofinnova Partners SAS, a French Corporation 2.7% 1,197,711 1,197,711 0 /s/ Antoine Papiernik Antoine Papiernik / Managing Partner
Antoine Papiernik 2.7% 1,197,711 1,197,711 0 /s/ Antoine Papiernik Antoine Papiernik
Henrijette Richter 2.7% 1,197,711 1,197,711 0 /s/ Henrijette Richter Henrijette Richter
Maina Bhaman 2.7% 1,197,711 1,197,711 0 /s/ Maina Bhaman Maina Bhaman
Graziano Seghezzi 2.7% 1,197,711 1,197,711 0 /s/ Graziano Seghezzi Graziano Seghezzi
Anta Gkelou 2.7% 1,197,711 1,197,711 0 /s/ Anta Gkelou Anta Gkelou
Karl Naegler 2.7% 1,197,711 1,197,711 0 /s/ Karl Naegler Karl Naegler